PMID- 23529229
OWN - NLM
STAT- MEDLINE
DCOM- 20131230
LR  - 20130326
IS  - 1673-4254 (Print)
IS  - 1673-4254 (Linking)
VI  - 33
IP  - 3
DP  - 2013 Mar
TI  - [Effect of nitrotyrosine on renal expressions of NF-kappaB, MCP-1 and TGF-beta1 in rats 
      with diabetic nephropathy].
PG  - 346-50
AB  - OBJECTIVE: To observe the effect of nitrotyrosine on renal expressions of nuclear 
      factor-kappaB (NF-kappaB), monocyte chemoattractant protein-1 (MCP-1), and transforming 
      growth factor-beta1 (TGF-beta1) in rats with diabetic nephropathy (DN). METHODS: Rat DN 
      models established by a single intraperitoneal injection of streptozotocin (STZ) 
      were randomly allocated into model group, nitrotyrosine group and ebselen group, 
      with untreated rats as the normal control group. The rats were given the 
      corresponding drugs for 8 weeks, and after the last administration, the 24-h 
      urinary protein level was measured and the kidneys of the rats were harvested for 
      detecting the protein and mRNA expressions of NF-kappaB, MCP-1 and TGF-beta1 with 
      immunohistochemistry and RT-PCR, respectively. The pathological changes of the 
      kidneys were assessed microscopically. RESULTS: Compared with those in the model 
      group, the 24-h urinary protein level and expressions of NF-kappaB, MCP-1 and TGF-beta1 
      mRNA and protein in the renal tissues were significantly increased by 
      nitrotyrosine treatment, which also caused worsened renal pathology, while 
      treatment with ebselen significantly ameliorated these changes. CONCLUSION: 
      Nitrotyrosine can up-regulate the mRNA and protein expressions of NF-kappaB, MCP-1 
      and TGF-beta1 and aggravate the inflammatory reaction in the renal tissue of DN rats 
      to promote the progression of DN.
FAU - Xu, Zhao-Zhong
AU  - Xu ZZ
AD  - Department of Emergency Medicine, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510282, China. xzz1008@163.com
FAU - Wang, Ming
AU  - Wang M
FAU - Wang, Yan-Jing
AU  - Wang YJ
FAU - Niu, Hong-Xin
AU  - Niu HX
FAU - Li, Xiao-Yun
AU  - Li XY
FAU - Zhou, Wei-Dong
AU  - Zhou WD
FAU - Zhu, Yan
AU  - Zhu Y
FAU - Long, Hai-Bo
AU  - Long HB
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Nan Fang Yi Ke Da Xue Xue Bao
JT  - Nan fang yi ke da xue xue bao = Journal of Southern Medical University
JID - 101266132
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (NF-kappa B)
RN  - 0 (Tgfb1 protein, rat)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 3604-79-3 (3-nitrotyrosine)
RN  - 42HK56048U (Tyrosine)
SB  - IM
MH  - Animals
MH  - Chemokine CCL2/*metabolism
MH  - Diabetes Mellitus, Experimental
MH  - Diabetic Nephropathies/*metabolism
MH  - Male
MH  - NF-kappa B/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Transforming Growth Factor beta1/*metabolism
MH  - Tyrosine/*analogs & derivatives/pharmacology
EDAT- 2013/03/27 06:00
MHDA- 2014/01/01 06:00
CRDT- 2013/03/27 06:00
PHST- 2013/03/27 06:00 [entrez]
PHST- 2013/03/27 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
PST - ppublish
SO  - Nan Fang Yi Ke Da Xue Xue Bao. 2013 Mar;33(3):346-50.